当前位置： SCI文献检索 > MOLECULAR CANCER THERAPEUTICS期刊下所有文献 > Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.

Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.

Abstract：

:Tissue transglutaminase 2 belongs to a family of transglutaminase proteins that confers mechanical resistance from proteolysis and stabilizes proteins. Transglutaminase 2 promotes transamidation between glutamine and lysine residues with the formation of covalent linkages between proteins. Transglutaminase 2 also interacts and forms complexes with proteins important in extracellular matrix organization and cellular adhesion. We have identified the novel finding that treatment of glioblastoma cells with transglutaminase 2 inhibitors promotes cell death and enhances sensitivity to chemotherapy. Treatment with either the competitive transglutaminase 2 inhibitor, monodansylcadaverine, or with highly specific small-molecule transglutaminase 2 inhibitors, KCA075 or KCC009, results in induction of apoptosis in glioblastoma cells. Treatment with these transglutaminase 2 inhibitors resulted in markedly decreased levels of the prosurvival protein, phosphorylated Akt, and its downstream targets. These changes promote a proapoptotic profile with altered levels of multiple intracellular proteins that determine cell survival. These changes include decreased levels of the antiapoptotic proteins, survivin, phosphorylated Bad, and phosphorylated glycogen synthetase kinase 3beta (GSK-3beta), and increased levels of the proapoptotic BH3-only protein, Bim. In vivo studies with s.c. murine DBT glioblastoma tumors treated with transglutaminase 2 inhibitors combined with the chemotherapeutic agent, N-N'-bis (2-chloroethyl)-N-nitrosourea (BCNU), decreased tumor size based on weight by 50% compared with those treated with BCNU alone. Groups treated with transglutaminase 2 inhibitors showed an increased incidence of apoptosis determined with deoxynucleotidyl transferase-mediated biotin nick-end labeling staining. These studies identify inhibition of transglutaminase 2 as a potential target to enhance cell death and chemosensitivity in glioblastomas.

journal_name

Mol Cancer Ther

journal_title

Molecular cancer therapeutics

authors

Yuan L,Choi K,Khosla C,Zheng X,Higashikubo R,Chicoine MR,Rich KM

doi

10.1158/1535-7163.MCT-04-0328

keywords:

subject

Has Abstract

pub_date

2005-09-01 00:00:00

pages

1293-302

issue

9

eissn

1535-7163

issn

1538-8514

pii

4/9/1293

journal_volume

4

pub_type

杂志文章

相关文献

MOLECULAR CANCER THERAPEUTICS文献大全
  • eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.

    abstract：:Activation of translation initiation is essential for the malignant phenotype and is emerging as a potential therapeutic target. Translation is regulated by the expression of translation initiation factor 4E (eIF4E) as well as the interaction of eIF4E with eIF4E-binding proteins (e.g., 4E-BP1). Rapamycin inhibits tran...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-2357

    authors： Soni A,Akcakanat A,Singh G,Luyimbazi D,Zheng Y,Kim D,Gonzalez-Angulo A,Meric-Bernstam F

    更新日期：2008-07-01 00:00:00

  • Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity.

    abstract：:Programmed cell death 4 (Pdcd4), originally identified as an inhibitor of murine cellular transformation, inhibits protein synthesis by directly interacting with eukaryotic initiation factor 4A (eIF4A) of the translation initiation complex. The relevance of Pdcd4 to a broad range of human cancers derived from multiple...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Jansen AP,Camalier CE,Stark C,Colburn NH

    更新日期：2004-02-01 00:00:00

  • UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.

    abstract：:This work is based on previous evidence showing that chemotactic sequence of the urokinase receptor (uPAR(88-92)) drives angiogenesis in vitro and in vivo in a protease-independent manner, and that the peptide Ac-Arg-Glu-Arg-Phe-NH(2) (RERF) prevents both uPAR(88-92)- and VEGF-induced angiogenesis. New N-acetylated an...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0949

    authors： Carriero MV,Bifulco K,Minopoli M,Lista L,Maglio O,Mele L,Di Carluccio G,De Rosa M,Pavone V

    更新日期：2014-05-01 00:00:00

  • Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones.

    abstract：:Marine invertebrates, algae, and microorganisms are prolific producers of novel secondary metabolites. Some of these secondary metabolites have the potential to be developed as chemotherapeutic agents for the treatment of a wide variety of diseases, including cancer. We describe here the mechanism leading to apoptosis...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0760

    authors： Whibley CE,McPhail KL,Keyzers RA,Maritz MF,Leaner VD,Birrer MJ,Davies-Coleman MT,Hendricks DT

    更新日期：2007-09-01 00:00:00

  • Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.

    abstract：:Despite frequent overexpression of numerous growth factor receptors by pancreatic ductal adenocarcinomas (PDAC), such as EGFR, therapeutic antibodies have not proven effective. Desmoplasia, hypovascularity, and hypoperfusion create a functional drug delivery barrier that contributes to treatment resistance. Drug combi...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0354

    authors： Wang J,Chan DKW,Sen A,Ma WW,Straubinger RM

    更新日期：2019-11-01 00:00:00

  • Evading Pgp activity in drug-resistant cancer cells: a structural and functional study of antitubulin furan metotica compounds.

    abstract：:Tumor resistance to antitubulin drugs resulting from P-glycoprotein (Pgp) drug-efflux activity, increased expression of the βIII tubulin isotype, and alterations in the drug-binding sites are major obstacles in cancer therapy. Consequently, novel antitubulin drugs that overcome these challenges are of substantial inte...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-11-1018

    authors： Nguyen TL,Cera MR,Pinto A,Lo Presti L,Hamel E,Conti P,Gussio R,De Wulf P

    更新日期：2012-05-01 00:00:00

  • MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival.

    abstract：:Although astrocytic brain tumors do not metastasize systemically, during tumorigenesis glioma cells adopt an invasive phenotype that is poorly targeted by conventional therapies; hence, glioma patients die of recurrence from the locally invasive tumor population. Our work is aimed at identifying and validating novel t...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0711

    authors： Demuth T,Reavie LB,Rennert JL,Nakada M,Nakada S,Hoelzinger DB,Beaudry CE,Henrichs AN,Anderson EM,Berens ME

    更新日期：2007-04-01 00:00:00

  • Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.

    abstract：:Breast cancer exhibits a propensity to metastasize to bone, resulting in debilitating skeletal complications associated with significant morbidity and poor prognosis. The cross-talk between metastatic cancer cells and bone is critical to the development and progression of bone metastases. We have shown the involvement...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-11-0277

    authors： Previdi S,Abbadessa G,Dalò F,France DS,Broggini M

    更新日期：2012-01-01 00:00:00

  • Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.

    abstract：:Near infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that combines the specificity of intravenously injected antibodies for targeting tumors with the toxicity induced by photosensitizers after exposure to near infrared (NIR) light. Herein, we evaluate the efficacy of NIR-PIT in a mouse model of dissemi...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0658

    authors： Sato K,Hanaoka H,Watanabe R,Nakajima T,Choyke PL,Kobayashi H

    更新日期：2015-01-01 00:00:00

  • Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.

    abstract：:Inhibitors of histone deacetylases have been approved for clinical application in cancer treatment. On the other hand, histone acetyltransferase (HAT) inhibitors have been less extensively investigated for their potential use in cancer therapy. In prostate cancer, the HATs and coactivators p300 and CBP are upregulated...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-11-0182

    authors： Santer FR,Höschele PP,Oh SJ,Erb HH,Bouchal J,Cavarretta IT,Parson W,Meyers DJ,Cole PA,Culig Z

    更新日期：2011-09-01 00:00:00

  • Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

    abstract：:Protein tyrosine kinases of the Janus kinase (JAK) family are associated with many cytokine receptors, which, on ligand binding, regulate important cellular functions such as proliferation, survival, and differentiation. In multiple myeloma, JAKs may be persistently activated due to a constant stimulation by interleuk...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-0149

    authors： Burger R,Le Gouill S,Tai YT,Shringarpure R,Tassone P,Neri P,Podar K,Catley L,Hideshima T,Chauhan D,Caulder E,Neilan CL,Vaddi K,Li J,Gramatzki M,Fridman JS,Anderson KC

    更新日期：2009-01-01 00:00:00

  • Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.

    abstract：:The secondary T790M mutation in epidermal growth factor receptor (EGFR) is the major mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). Although irreversible EGFR TKIs, such as afatinib or dacomitinib, have been introduced to overcome the acquired resistanc...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-12-0311

    authors： Kim SM,Kwon OJ,Hong YK,Kim JH,Solca F,Ha SJ,Soo RA,Christensen JG,Lee JH,Cho BC

    更新日期：2012-10-01 00:00:00

  • Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.

    abstract：:The cytosine analogue decitabine alters hematopoietic differentiation. For example, decitabine treatment increases self-renewal of normal hematopoietic stem cells. The mechanisms underlying decitabine-induced shifts in differentiation are poorly understood, but likely relate to the ability of decitabine to deplete the...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-10-0191

    authors： Hu Z,Negrotto S,Gu X,Mahfouz R,Ng KP,Ebrahem Q,Copelan E,Singh H,Maciejewski JP,Saunthararajah Y

    更新日期：2010-06-01 00:00:00

  • Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax.

    abstract：:Hsp90 is widely overexpressed in cancer cells and believed to be essential for the maintenance of malignant phenotypes. Targeting Hsp90 by small molecules has shown promise in solid and hematologic malignancies, which likely involves degradation of client oncoproteins in a cell-type-specific manner. In this study, we ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0284

    authors： He K,Zheng X,Zhang L,Yu J

    更新日期：2013-11-01 00:00:00

  • The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.

    abstract：:Neuroblastoma is the most common extracranial solid tumor of childhood. The activity of J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester), an enzymatically activated melphalan prodrug, was evaluated in neuroblastoma models in vitro and in vivo. Seven neuroblastoma cell lines with various levels of drug resistance...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0156

    authors： Wickström M,Johnsen JI,Ponthan F,Segerström L,Sveinbjörnsson B,Lindskog M,Lövborg H,Viktorsson K,Lewensohn R,Kogner P,Larsson R,Gullbo J

    更新日期：2007-09-01 00:00:00

  • Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen.

    abstract：:With current techniques, it remains a challenge to assess coregulator binding of nuclear receptors, for example, the estrogen receptor alpha (ERα). ERα is critical in many breast tumors and is inhibited by antiestrogens such as tamoxifen in cancer therapy. ERα is also modified by acetylation and phosphorylation that a...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-11-0855

    authors： Houtman R,de Leeuw R,Rondaij M,Melchers D,Verwoerd D,Ruijtenbeek R,Martens JW,Neefjes J,Michalides R

    更新日期：2012-04-01 00:00:00

  • Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.

    abstract：:Photodynamic therapy (PDT) induces the expression of the hypoxia-inducible factor 1alpha (HIF-1alpha) subunit of the HIF-1 transcription factor and its target genes in vitro and in vivo. PDT also induces the expression of the enzyme cyclooxygenase-2 and its metabolite, prostaglandin E2 (PGE2). PGE2 and hypoxia act ind...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0421

    authors： Mitra S,Cassar SE,Niles DJ,Puskas JA,Frelinger JG,Foster TH

    更新日期：2006-12-01 00:00:00

  • Mechanism of differentiation-enhanced photodynamic therapy for cancer: upregulation of coproporphyrinogen oxidase by C/EBP transcription factors.

    abstract：:The efficacy of photodynamic therapy (PDT) for epithelial cancers is increased when PDT is combined with calcitriol (Vit D), a form of differentiation therapy (DT). Here, we describe an underlying mechanism for this effect. Differentiation-promoting agents are known to upregulate CCAAT/enhancer-binding proteins (C/EBP...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0047

    authors： Anand S,Hasan T,Maytin EV

    更新日期：2013-08-01 00:00:00

  • p37 Induces tumor invasiveness.

    abstract：:Previous studies have shown a statistically significant correlation between human carcinomas and monoclonal antibody detection of a Mycoplasma hyorhinis-encoded protein known as p37. A potential mechanism of p37 is that it might promote invasion and metastasis. Recombinant p37 enhanced the invasiveness of two prostate...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0040

    authors： Ketcham CM,Anai S,Reutzel R,Sheng S,Schuster SM,Brenes RB,Agbandje-McKenna M,McKenna R,Rosser CJ,Boehlein SK

    更新日期：2005-07-01 00:00:00

  • 10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models.

    abstract：:In recent years, HER3 has increasingly been implicated in the progression of a variety of tumor types and in acquired resistance to EGFR and HER2 therapies. Whereas EGFR and HER2 primarily signal through the MAPK pathway, HER3, as a heterodimer with EGFR or HER2, potently activates the PI3K pathway. Despite its critic...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-0515

    authors： Thakkar D,Sancenon V,Taguiam MM,Guan S,Wu Z,Ng E,Paszkiewicz KH,Ingram PJ,Boyd-Kirkup JD

    更新日期：2020-02-01 00:00:00

  • Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.

    abstract：:HER2-positive breast cancer is currently managed with chemotherapy in combination with specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients with HER2-positive tumors do not respond to trastuzumab (primary resistance) or either recur (acquired resistance), mostly due to molecular ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-1172

    authors： Zazo S,González-Alonso P,Martín-Aparicio E,Chamizo C,Luque M,Sanz-Álvarez M,Mínguez P,Gómez-López G,Cristóbal I,Caramés C,García-Foncillas J,Eroles P,Lluch A,Arpí O,Rovira A,Albanell J,Madoz-Gúrpide J,Rojo F

    更新日期：2020-08-01 00:00:00

  • Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

    abstract：:B-Raf is an important mediator of cell proliferation and survival signals transduced via the Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors, including papillary thyroid carcinoma, but the precise role of B-Raf as a therapeutic target for thyroid carcinoma is still under investigation. We ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0449

    authors： Mitsiades CS,Negri J,McMullan C,McMillin DW,Sozopoulos E,Fanourakis G,Voutsinas G,Tseleni-Balafouta S,Poulaki V,Batt D,Mitsiades N

    更新日期：2007-03-01 00:00:00

  • Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.

    abstract：:The PI3K/AKT/mTOR pathway, which is aberrantly stimulated in many cancer cells, has emerged as a target for therapy. However, mTORC1/S6K also mediates negative feedback loops that attenuate upstream signaling. Suppression of these feedback loops opposes the growth-suppressive effects of mTOR inhibitors and leads to dr...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0669

    authors： Soares HP,Ming M,Mellon M,Young SH,Han L,Sinnet-Smith J,Rozengurt E

    更新日期：2015-04-01 00:00:00

  • Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

    abstract：:Notch signaling is aberrantly activated in approximately one third of non-small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in preclinical models of NSCLC. Chemosensitivity assays were performed on 14...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-0439

    authors： Morgan KM,Fischer BS,Lee FY,Shah JJ,Bertino JR,Rosenfeld J,Singh A,Khiabanian H,Pine SR

    更新日期：2017-12-01 00:00:00

  • The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth.

    abstract：:DNA damage repair capacity is required for cells to survive catastrophic DNA damage and proliferate under conditions of intratumoral stress. The ability of the minor histone protein H2AX to serve as a hub for the assembly of a productive DNA damage repair complex is a necessary step in preventing DNA damage-induced ce...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0057

    authors： Wang Y,Pandey RN,Riffle S,Chintala H,Wikenheiser-Brokamp KA,Hegde RS

    更新日期：2018-08-01 00:00:00

  • Synergistic enhancement of TRAIL- and tumor necrosis factor alpha-induced cell death by a phenoxazine derivative.

    abstract：:2-Amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one (Phx-1) has been developed as a novel phenoxazine derivative having an anticancer activity on a variety of cancer cell lines as well as transplanted tumors in mice with minimal toxicity to normal cells. We examined the effects of Phx-1 on Jurkat cells, a ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0067

    authors： Hara K,Okamoto M,Aki T,Yagita H,Tanaka H,Mizukami Y,Nakamura H,Tomoda A,Hamasaki N,Kang D

    更新日期：2005-07-01 00:00:00

  • A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

    abstract：:Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy with one of the worst outcomes among all cancers. PDA often recurs after initial treatment to result in patient death despite the use of chemotherapy or radiation therapy. PDA contains a subset of tumor-initiating cells capable of extensive self-renewa...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-10-0370

    authors： Rajeshkumar NV,Rasheed ZA,García-García E,López-Ríos F,Fujiwara K,Matsui WH,Hidalgo M

    更新日期：2010-09-01 00:00:00

  • Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.

    abstract：:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effective ways to treat gli...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-0640

    authors： Hingtgen S,Ren X,Terwilliger E,Classon M,Weissleder R,Shah K

    更新日期：2008-11-01 00:00:00

  • Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation.

    abstract：:This study aims to explore whether E545K, the most common hotspot mutation of PIK3CA in cervical cancer, confers radioresistance to cervical cancer cells, to demonstrate the underling mechanism, and to develop the effective targets. SiHa and MS751 cells with PIK3CA-WT and PIK3CA-E545K were established by lentiviral tr...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-19-0309

    authors： Jiang W,Wu Y,He T,Zhu H,Ke G,Xiang L,Yang H

    更新日期：2020-02-01 00:00:00

  • The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach.

    abstract：:A novel series of 3,5-diaryl-oxadiazoles was identified as apoptosis-inducing agents through our cell and chemical genetics-based screening assay for compounds that induce apoptosis using a chemical genetics approach. Several analogues from this series including MX-74420 and MX-126374 were further characterized. MX-12...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-04-0333

    authors： Jessen KA,English NM,Yu Wang J,Maliartchouk S,Archer SP,Qiu L,Brand R,Kuemmerle J,Zhang HZ,Gehlsen K,Drewe J,Tseng B,Cai SX,Kasibhatla S

    更新日期：2005-05-01 00:00:00